Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | GLRA1 | P23415 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12205439 | 0.84 | PPARA (0.45) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL27584559 | 0.82 | GABRA1 (0.53) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL2484139 | 0.81 | GABRA1 (0.51) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL2485093 | 0.81 | GABRA1 (0.51) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL21660797 | 0.79 | GABRA1 (0.50) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL28078271 | 0.77 | GABRA1 (0.78) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL27262232 | 0.77 | GAA (0.57) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL25760150 | 0.77 | GABRA1 (0.47) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL4319072 | 0.75 | GABRA1 (0.63) | GABRA1GABRB1GABRB2CA1CA2 | |
| SCHEMBL2341096 | 0.75 | GABRA1 (0.58) | GABRA1GABRB1GABRB2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945705-B1 | PHOTOLATENT SYSTEMS | BASF SE (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-7820865-B2 | Photolatent systems | CIBA CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820865-B2 | Photolatent systems | CIBA CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090162307-A1 | Photolatent Systems | CIBA CORP. | 2009-06-25 | — | — | US | disclosed |
| US-20090162307-A1 | Photolatent Systems | CIBA CORP. | 2009-06-25 | — | — | US | disclosed |
| EP-1945705-A1 | PHOTOLATENT SYSTEMS | Ciba Holding Inc. (CH) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007054446-A1 | PHOTOLATENT SYSTEMS | CIBA HOLDING INC. (CH) | 2007-05-18 | — | — | WO | disclosed |
| EP-1223933-A2 | 5-MEMBERED HETEROCYCLE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001026656-A2 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND USE THEREOF AS MONOAMINE OXIDASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162307-A1 | Photolatent Systems | CCNT1, CCNT2, C1S | GABRA1 3210/4885GABRB1 3049/4885GABRB2 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.